Kolexia
Benmammar Kheir-Eddine Oncologie médicale
Benmammar Kheir-Eddine
Oncologie médicale
Hôpital Emile Roux Le Puy-en-Velay
Le Puy-en-Velay, France
34 Activités
0 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Tumeurs du sein Tumeurs du sein triple-négatives Carcinome canalaire du sein Neuropathies périphériques Tumeurs colorectales Pathologic Complete Response Névralgie {{person.topmesh9.name}} {{person.topmesh10.name}}

Collaborateurs

Voir plus
Drebit Yuriy
Drebit Yuriy
Centre Hospitalier de Beziers, Béziers, France
Kokorian Romain
Kokorian Romain
Cabinet libéral, Rouen, France
Liu Kun Lun
Liu Kun Lun
Hôpital Hautepierre, Strasbourg, France
Khalil Ahmed
Khalil Ahmed
Hôpital Tenon, Paris, France

Industries

Voir plus
B3TSI
331 collaboration(s)
Dernière en 2023
A+A
135 collaboration(s)
Dernière en 2023
IQVIA
46 collaboration(s)
Dernière en 2023
PASCALEO
10 collaboration(s)
Dernière en 2022

Dernières activités

Voir plus
Colorectal Cancer Survivors Suffering From Sensory Chemotherapy-Induced Peripheral Neuropathy Are Not a Homogenous Group: Secondary Analysis of Patients' Profiles With Oxaliplatin-Induced Peripheral Neuropathy.
Frontiers in pharmacology   04 novembre 2021
Long-Term Prevalence of Sensory Chemotherapy-Induced Peripheral Neuropathy for 5 Years after Adjuvant FOLFOX Chemotherapy to Treat Colorectal Cancer: A Multicenter Cross-Sectional Study.
Journal of clinical medicine   27 juillet 2020
Multicentric neoadjuvant pilot Phase II study of cetuximab combined with docetaxel in operable triple negative breast cancer.
International journal of cancer   28 décembre 2015
Can pathologic complete response (pCR) be used as a surrogate marker of survival after neoadjuvant therapy for breast cancer?
Critical reviews in oncology/hematology   04 mars 2015
Multicentric neoadjuvant phase II study of panitumumab combined with an anthracycline/taxane-based chemotherapy in operable triple-negative breast cancer: identification of biologically defined signatures predicting treatment impact.
Annals of oncology : official journal of the European Society for Medical Oncology   14 mai 2014
TVA: Phase II Trial Assessing Neoadjuvant Therapy With FEC 100 Followed by Taxotere® (Docetaxel) Plus Vectibix® (Panitumumab) in Patients With Operable, HR and Her-2 Negative Breast Cancer. TVA Study
Essai Clinique (Centre Jean-Perrin)   20 mars 2014
Assessment of the Efficacy of a Neoadjuvant Combination: "Chemotherapy-targeted Therapy" in Breast Cancer.: Phase II Pilot Study Evaluating the Neoadjuvant Combination "Taxotere (Docetaxel) and Erbitux (Cetuximab) in Operable and "Triple Negative" Breast Cancer Patients. TENEO Study.
Essai Clinique (Sanofi)   19 mars 2014
{{person.lastact8.name}}
{{person.lastact8.jour}}   {{person.lastact8.date}}
{{person.lastact9.name}}
{{person.lastact9.jour}}   {{person.lastact9.date}}
{{person.lastact10.name}}
{{person.lastact10.jour}}   {{person.lastact10.date}}